Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics: GC/MS analysis of PGI2 and PGI3 levels.
The enzymatic metabolites, 6-keto-PGF1 alpha and delta 17-6-keto-PGF1 alpha, were measured by gas chromatography/high resolution-selected ion monitoring (GC/HR-SIM) as markers of prostaglandin I2 (PGI2) and prostacyclin (PGI3) production in human sera. Eicosapentaenoic acid (EPA) ethyl ester (1.8 g/day) was administered to 12 noninsulin-dependent diabetes mellitus (NIDDM) patients for 2 weeks. Forty patients with similar NIDDM were followed as a control group. PGI3 production in sera was significantly increased in the EPA intake group in comparison with the control group. These findings suggest that EPA intake prevents complications of diabetes mellitus, such as microangiopathy and vaso-occlusive diseases.
Nishikawa
M
M
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
Hishinuma
T
T
Nagata
K
K
Koseki
Y
Y
Suzuki
K
K
Mizugaki
M
M
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism*; D015118:Eicosapentaenoic Acid / Q000494:pharmacology*; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000096:biosynthesis* / Q000097:blood; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism*; D012016:Reference Values
D010975:Platelet Aggregation Inhibitors; D015121:6-Ketoprostaglandin F1 alpha; C034240:prostaglandin I3; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol